Seven distinct studies realized improved symptom control, patient engagement, and satisfaction, in parallel with reductions in healthcare utilization and costs; IBD study earned Presidential...

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus...

The highly anticipated 2025 IDF World Dairy Summit took place from October 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences...

Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that management will participate in the following investor conferences in November: Event:...

- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming...

-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a...

The Asia Pacific Circular Economy Roundtable & Hotspot 2025 (APCER & Hotspot 2025) concluded successfully in Taipei. Co-hosted by Taiwan's Ministry of Environment, Ministry of Economic Affairs,...